PDF(Pubmed)
Abstract：
BACKGROUND: To evaluate the technical success and patient safety of magnetic resonance-guided percutaneous microwave coagulation (MR-guided PMC) for breast malignancies.
METHODS: From May 2018 to December 2019, 26 patients with breast tumors measuring 2 cm or less were recruited to participate in a prospective, single-institution clinical study. The primary endpoint of this study was the evaluation of treatment efficacy for each patient. Histochemical staining with α-nicotinamide adenine dinucleotide and reduced (NADH)-diaphorase was used to determine cell viability following and efficacy of PMC. The complications and self-reported sensations from all patients during and after ablation were also assessed. The technical success of the PMC procedure was defined when the area of the NADH-diaphorase negative region fully covered the hematoxylin-eosin (H&E) staining region in the tumor.
RESULTS: All patients had a complete response to ablation with no residual carcinoma on histopathological specimen. The mean energy, ablation duration, and procedure duration per tumor were 36.0 ± 4.2 kJ, 252.9 ± 30.9 S, and 104.2 ± 13.5 min, respectively. During the ablation, 14 patients underwent prolonged ablation time, and 1 patient required adjusting of the antenna position. Eleven patients had feelings of subtle heat or swelling, and 3 patients experienced slight pain. After ablation, one patient took two painkillers because of moderate pain, and no patients had postoperative oozing or other complications after PMC. Induration around the ablation area appeared in 16 patients.
CONCLUSIONS: MR-guided PMC of small breast tumors is feasible and could be applied in clinical practice in the future.
UNASSIGNED: MR-guided PMC of small breast tumors is feasible and could be applied in clinical practice in the future.
CONCLUSIONS: • MR-guided PMC of small breast tumors is feasible. • PMC was successfully performed for all patients. • All patients were satisfied with the final cosmetic result.
METHODS: From May 2018 to December 2019, 26 patients with breast tumors measuring 2 cm or less were recruited to participate in a prospective, single-institution clinical study. The primary endpoint of this study was the evaluation of treatment efficacy for each patient. Histochemical staining with α-nicotinamide adenine dinucleotide and reduced (NADH)-diaphorase was used to determine cell viability following and efficacy of PMC. The complications and self-reported sensations from all patients during and after ablation were also assessed. The technical success of the PMC procedure was defined when the area of the NADH-diaphorase negative region fully covered the hematoxylin-eosin (H&E) staining region in the tumor.
RESULTS: All patients had a complete response to ablation with no residual carcinoma on histopathological specimen. The mean energy, ablation duration, and procedure duration per tumor were 36.0 ± 4.2 kJ, 252.9 ± 30.9 S, and 104.2 ± 13.5 min, respectively. During the ablation, 14 patients underwent prolonged ablation time, and 1 patient required adjusting of the antenna position. Eleven patients had feelings of subtle heat or swelling, and 3 patients experienced slight pain. After ablation, one patient took two painkillers because of moderate pain, and no patients had postoperative oozing or other complications after PMC. Induration around the ablation area appeared in 16 patients.
CONCLUSIONS: MR-guided PMC of small breast tumors is feasible and could be applied in clinical practice in the future.
UNASSIGNED: MR-guided PMC of small breast tumors is feasible and could be applied in clinical practice in the future.
CONCLUSIONS: • MR-guided PMC of small breast tumors is feasible. • PMC was successfully performed for all patients. • All patients were satisfied with the final cosmetic result.
摘要：
背景：评估磁共振引导经皮微波凝固术（MR引导PMC）治疗乳腺恶性肿瘤的技术成功和患者安全性。
方法：从2018年5月至2019年12月，招募26例2厘米或以下的乳腺肿瘤患者参加前瞻性，单机构临床研究。这项研究的主要终点是评估每位患者的治疗效果。使用α-烟酰胺腺嘌呤二核苷酸和还原的(NADH)-黄递酶的组织化学染色来确定PMC后的细胞活力和功效。还评估了所有患者在消融期间和之后的并发症和自我报告的感觉。当NADH-心肌黄递酶阴性区域的区域完全覆盖肿瘤中的苏木精-伊红(H&E)染色区域时,确定PMC程序的技术成功。
结果：所有患者对消融有完全反应，组织病理学标本上没有残留癌。平均能量，消融持续时间,每个肿瘤的手术持续时间为36.0±4.2kJ，252.9±30.9S，104.2±13.5分钟，分别。在消融期间,14例患者接受了延长的消融时间，1名患者需要调整天线位置。11名患者有轻微的发热或肿胀的感觉，3例患者出现轻微疼痛。消融后,一个病人因为中度疼痛服用了两种止痛药,PMC术后无渗血或其他并发症。16例患者出现消融区域周围的持续时间。
结论：MR引导下乳腺小肿瘤的PMC是可行的，可用于临床。
■MR引导下乳腺小肿瘤的PMC是可行的，可以在未来的临床实践中应用。
结论：•MR引导下乳腺小肿瘤的PMC是可行的。•对所有患者成功进行了PMC。•所有患者对最终的美容结果满意。
方法：从2018年5月至2019年12月，招募26例2厘米或以下的乳腺肿瘤患者参加前瞻性，单机构临床研究。这项研究的主要终点是评估每位患者的治疗效果。使用α-烟酰胺腺嘌呤二核苷酸和还原的(NADH)-黄递酶的组织化学染色来确定PMC后的细胞活力和功效。还评估了所有患者在消融期间和之后的并发症和自我报告的感觉。当NADH-心肌黄递酶阴性区域的区域完全覆盖肿瘤中的苏木精-伊红(H&E)染色区域时,确定PMC程序的技术成功。
结果：所有患者对消融有完全反应，组织病理学标本上没有残留癌。平均能量，消融持续时间,每个肿瘤的手术持续时间为36.0±4.2kJ，252.9±30.9S，104.2±13.5分钟，分别。在消融期间,14例患者接受了延长的消融时间，1名患者需要调整天线位置。11名患者有轻微的发热或肿胀的感觉，3例患者出现轻微疼痛。消融后,一个病人因为中度疼痛服用了两种止痛药,PMC术后无渗血或其他并发症。16例患者出现消融区域周围的持续时间。
结论：MR引导下乳腺小肿瘤的PMC是可行的，可用于临床。
■MR引导下乳腺小肿瘤的PMC是可行的，可以在未来的临床实践中应用。
结论：•MR引导下乳腺小肿瘤的PMC是可行的。•对所有患者成功进行了PMC。•所有患者对最终的美容结果满意。
